News | August 25, 2010

AGA Medical Files Suit Against W.L. Gore Alleging Patent Infringement

The Gore Helex septal occluder.

August 25, 2010 – Alleging infringement of a patent for its transcatheter cardiac septal occluder devices, AGA Medical Holdings Inc. said it filed a lawsuit against W.L. Gore & Associates.

AGA alleges Gore is infringing its U.S. Patent No. 5,994,738, which covers certain Amplatzer transcatheter occlusion products for the treatment of structural heart defects. AGA is seeking damages against Gore and a permanent injunction prohibiting them from manufacturing and selling the Gore Helex Septal Occluder both in the United States and abroad.

AGA Amplatzer occlusion devices offer minimally invasive, transcatheter treatments in cardiac defect closure. AGA has occlusion devices approved to close seven different structural heart defects.

The company has been a market leader in this field, but its market share has been seriously challenged by Gore’s Helex device.

For more information: www.amplatzer.com, www.goremedical.com

Related Content

FDA Approves Abbott's Amplatzer Piccolo Occluder
News | Structural Heart Occluders | January 16, 2019
Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...
FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Overlay Init